What is done in Phase 4 of drug development?

• A. Preclinical animal toxicology testing.
• B. Phase 1 safety testing in humans.
• C. Discovery of new drug targets.
• D. Manufacturing scale-up activities of finished product, and formulation may be modified slightly; occurs after the NDA is submitted and before approval by FDA, and not all drugs undergo this phase

Answer: (D)

Phase 4 is post-marketing surveillance, done after a drug has been approved and is on the market. This phase focuses on ongoing safety and effectiveness in the real world, collecting data on rare or long-term adverse effects, drug interactions, and how the medicine works across broader patient populations. It often involves pharmacovigilance work, spontaneous adverse event reporting, and sometimes additional post-marketing studies or changes to labeling and risk-management plans.

The described option centers on manufacturing scale-up happening after the NDA is submitted and before FDA approval. That step is part of late-stage development and manufacturing validation prior to approval, not Phase 4. Changes in formulation or scale-up after approval, if they occur, are handled through regulatory supplements rather than defining Phase 4.